\
&
Contact us
Published on | 1 year ago
ProgrammesThe following calls for the CL5 destinations "Sustainable, secure and competitive energy supply" and "Efficient, sustainable and inclusive energy" use" are now open:
|
HORIZON-CL5-2024-D3-02-01 |
|
|
HORIZON-CL5-2024-D3-02-02 |
Development of next generation synthetic renewable fuel technologies |
|
HORIZON-CL5-2024-D3-02-03 |
|
|
HORIZON-CL5-2024-D3-02-04 |
|
|
HORIZON-CL5-2024-D3-02-05 |
|
|
HORIZON-CL5-2024-D3-02-06 |
|
|
HORIZON-CL5-2024-D3-02-07 |
|
|
HORIZON-CL5-2024-D3-02-08 |
|
|
HORIZON-CL5-2024-D3-02-09 |
|
|
HORIZON-CL5-2024-D3-02-10 |
|
|
HORIZON-CL5-2024-D3-02-11 |
|
|
HORIZON-CL5-2024-D3-02-12 |
|
|
HORIZON-CL5-2024-D3-02-13 |
Support to the activities of the SET Plan Key Action area Renewable fuels and bioenergy |
|
HORIZON-CL5-2024-D4-02-01 |
Industrialisation of sustainable and circular deep renovation workflows (Built4People Partnership) |
|
HORIZON-CL5-2024-D4-02-02 |
|
|
HORIZON-CL5-2024-D4-02-03 |
|
|
HORIZON-CL5-2024-D4-02-04 |
|
|
HORIZON-CL5-2024-D4-02-05 |
You can rewatch the previous Info day-CL5 presentations with relevant information on these calls via this link
Do not hesitate to contact your NCP if you have further questions or need help finding partners.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.